In the wake of declining revenues, patent expiries, restructuring, strategic shifts and the ever changing industry landscape, Pharma and biotech companies need to expand beyond their core business and seek additional revenue streams as well as divest some of the assets. Additionally with an everincreasing number of startups thirsting for funding - clients have an opportunity to seek out quick-wins, promising technologies, whether through co-development partnerships or licensing in new products and drug delivery platforms.
Seyon orchestrates divestiture deals against challenging timetables while providing guidance during every phase of the process. We are experts in pharmaceutical & biotech divestments, with an impressive record of successful divestment transactions for many of our clients.
